Accordingly, genetic studies aimed at identifying SL interactors of SKP1 are highly warranted as the SL interactors are candidate drug targets that when inhibited are predicted to induce the selective killing of cancer cells harboring SKP1 defects. Here, SKP1 is linked to cancer.